Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

SEOM guidelines for endometrial cancer.

Ana Oaknin1, Víctor Rodríguez-Freixinós, Isabela Díaz de Corcuera

  • 1Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. amoaknin@vhebron.net

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|June 23, 2012
PubMed
Summary

Endometrial cancer (EC) affects many women, with most diagnosed early. However, a subset of patients has poor prognosis, highlighting the need for better adjuvant treatment strategies and therapies for recurrent disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platinum Rechallenge in Platinum-Resistant Ovarian Cancer: Clinical Outcomes and the Impact of BRCA Status.

Cancers·2026
Same author

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

NPJ precision oncology·2026
Same author

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Quality and safety of research biopsies in oncology clinical trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Area of Science:

  • Gynecologic Oncology
  • Cancer Research
  • Clinical Trials

Background:

  • Endometrial cancer (EC) is the most frequent gynecological malignancy in developing nations.
  • While many EC patients achieve high 5-year survival rates (>85%) due to early diagnosis, a significant subgroup faces a poor prognosis.
  • Pathological and molecular features contribute to varied patient outcomes, necessitating refined treatment protocols.

Purpose of the Study:

  • To address the lack of consensus on adjuvant treatment for endometrial cancer.
  • To investigate optimal patient selection, treatment modalities (chemotherapy, radiotherapy, or combination), and timing for adjuvant therapy.
  • To highlight the urgent need for improved therapeutic strategies for metastatic or recurrent EC, given poor responses to current treatments.

Main Methods:

More Related Videos

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Related Experiment Videos

Last Updated: May 21, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

  • Review of current clinical practices and outcomes in endometrial cancer management.
  • Identification of ongoing clinical trials addressing adjuvant treatment controversies.
  • Analysis of survival data for patients with advanced or recurrent disease.

Main Results:

  • Early-stage EC generally has a favorable prognosis.
  • A subset of EC patients exhibits poor prognosis linked to specific pathological and molecular characteristics.
  • Current treatment options for metastatic or recurrent EC are limited, with suboptimal responses to standard chemotherapy.

Conclusions:

  • Adjuvant treatment decisions in EC remain complex, with ongoing research to define optimal strategies.
  • Further investigation is crucial to improve outcomes for high-risk and recurrent endometrial cancer patients.
  • Development of novel second-line treatments is essential for improving survival in advanced EC.